Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Oncology ; 78(1): 54-61, 2010.
Article in English | MEDLINE | ID: mdl-20215786

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the efficacy of adjuvant chemotherapy with etoposide, Adriamycin and cisplatin (EAP) after potentially curative resections for gastric cancer. METHODS: After surgery, patients were randomly assigned to the EAP or control arm. Chemotherapy included 3 courses, administered every 28 days. Each cycle consisted of doxorubicin (20 mg/m(2)) on days 1 and 7, cisplatin (40 mg/m(2)) on days 2 and 8, and etoposide (120 mg/m(2)) on days 4, 5, and 6. RESULTS: Of 309 eligible patients, 141 were allocated to chemotherapy and 154 to the supportive care group. Four (2.8%) treatment-related deaths were recorded, including 3 due to septic complications of myelosuppression and 1 due to cardiocirculatory failure. Grade 3 or 4 toxicities were found in 17 (22%) patients. According to the intention-to-treat analysis, the median survival was 41.3 months (95% confidence interval, 24.5-58.2) and 35.9 months (95% confidence interval, 25.5-46.3) in the chemotherapy and control group, respectively (p = 0.398). Subgroup analysis revealed survival benefit from chemotherapy in patients with tumors infiltrating the serosa and in those with 7-15 metastatic lymph nodes. CONCLUSION: Three cycles of EAP regimen postoperatively offer no survival advantage in gastric cancer patients.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Stomach Neoplasms/drug therapy , Adenocarcinoma/surgery , Aged , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Gastrectomy , Humans , Male , Middle Aged , Stomach Neoplasms/surgery , Survival Analysis
2.
Hepatogastroenterology ; 52(66): 1911-5, 2005.
Article in English | MEDLINE | ID: mdl-16334805

ABSTRACT

BACKGROUND/AIMS: The aim of the study was to review cases of gastric cancers in elderly adults (70 years of age and older), and compare demographic, clinical, pathologic features and outcomes of surgical treatment with younger patients (below 70 years of age). METHODOLOGY: The analysis included 3431 patients treated for gastric cancer between 1977 and 1998 at eight university surgical centers cooperating for the Polish Gastric Cancer Study Group (PGCSG). Patients were analyzed retrospectively according to data obtained from standardized forms and divided into two groups: group I--patients 70 years of age and over, group II--younger patients. RESULTS: There were no significant differences between these two groups in clinical symptoms at the time of diagnosis and tumor advancement. The incidence of the intestinal type according to Lauren (55.9% vs. 43.9%;p<0.05) and distally-located cancers (40.8% vs. 31.3%; p<0.05) was higher in group I. Total gastrectomies and extended lymph node dissection were performed more often in younger patients. There were no significant differences in postoperative complications between both groups, except the higher incidence of abdominal abscesses in the younger group. The overall 5-year survival was 24% and 35% for group I and II, respectively (p<0.05), and increased to 35% and 53% after radical resections, respectively. However, there were no statistically significant differences in stage-specific survival between both groups. CONCLUSIONS: Surgical resection is the method of choice in the treatment of gastric cancer. Age of the patients is not a contraindication to surgical treatment of gastric cancer.


Subject(s)
Adenocarcinoma/mortality , Adenocarcinoma/surgery , Postoperative Complications/epidemiology , Stomach Neoplasms/mortality , Stomach Neoplasms/surgery , Adenocarcinoma/pathology , Adult , Age Factors , Aged , Aged, 80 and over , Biopsy, Needle , Chi-Square Distribution , Cohort Studies , Female , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Staging , Postoperative Complications/pathology , Probability , Prognosis , Retrospective Studies , Risk Assessment , Stomach Neoplasms/pathology , Survival Analysis , Treatment Outcome
3.
Acta Chir Belg ; 105(2): 175-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15906909

ABSTRACT

BACKGROUND & AIM: To analyze the clinical impact and cost-effectiveness of parenteral immunonutrition (PN). METHODS: Prospective clinical trial of a group of 105 patients operated on for gastric carcinoma between 2001-2003. During the postoperative period, patients were randomly allocated to one of three groups: standard PN (A), PN + glutamine (B) and PN + omega-3-FA (C). The rate and type of complications, hepatic and renal function, cost and treatment tolerance in all groups were analyzed. RESULTS: Postoperative complications were observed in 11 patients (36.6%) in group A, in 7 (23.3%) in B and in 8 (26.6%) in C. The most common complication was pneumonia. Prealbumin concentration and TLC increased faster in groups B and C. The length of hospital stay was significantly shorter in the immunonutrition groups. The cost of PN was highest in C group, while cost of hospital stay was longer in A. CONCLUSIONS: Immunostimulating parenteral nutrition helps to reduce the number of infectious complications, improves the function of the immune system, and has no influence on surgical complications, hepatic and renal function and protein synthesis. The cost of immunostimulating treatment based on omega-3-unsaturated fatty acids is higher than standard.


Subject(s)
Carcinoma/surgery , Fatty Acids, Omega-3/therapeutic use , Glutamine/therapeutic use , Malnutrition/therapy , Parenteral Nutrition/methods , Stomach Neoplasms/surgery , Carcinoma/pathology , Dietary Supplements , Female , Follow-Up Studies , Gastrectomy/methods , Humans , Male , Malnutrition/diagnosis , Nutritional Requirements , Postoperative Period , Prospective Studies , Risk Assessment , Stomach Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...